There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
Africa Blood Bone Marrow Crispr (DNA) Developing Countries Drugs (Pharmaceuticals) Food and Drug Administration Genetic Engineering Genetics and Heredity Income Inequality Sickle Cell Anemia Stem Cells Therapy and Rehabilitation Transplants Vertex Pharmaceuticals Inc your-feed-healthcare your-feed-science
Leave a Reply